Sensyne Health and George Eliot Hospital NHS Trust sign strategic research agreement

New deal provides access to anonymised patient datasets for analysis using clinical artificial intelligence technology

Sensyne Health, the British clinical AI technology company, has announced it has signed a Strategic Research Agreement (SRA) with George Eliot Hospital NHS Trust.

The deal will allow Sensyne Health to analyse anonymised patient data using clinical artificial intelligence (clinical AI) technology.

The purpose of the research is to derive new insights that will improve the care of NHS trust patients and help to find new treatments.

This new SRA provides rich longitudinal anonymised data for analysis covering 746,000 hospital admissions from a patient population of approximately 300,000.

The trust will receive a £2.5m equity stake in Sensyne Health and will also benefit from royalties that arise from any discoveries.

The royalties the trust receives will be reinvested back into the NHS, which can fund further research and can help deliver higher-quality patient care at lower cost.

George Eliot Hospital NHS Trust joins existing SRAs the company has in place with South Warwickshire Hospital, Oxford University Hospitals and Chelsea & Westminster Hospital.

The trust provides anonymised patient data that expands the breadth, depth, and longitudinal nature of Sensyne’s existing NHS partners.

The value is enhanced by their membership of the Foundation Group formed by South Warwickshire NHS Foundation Trust, and Sensyne’s other new partner, Wye Valley NHS Trust.

Lord (Paul) Drayson, chief executive of Sensyne Health, said: “We are delighted that the George Eliot Hospital NHS Trust has joined our research partnership in clinical AI.

“Together, we aim to make new discoveries that will improve care for patients, accelerate medical research and provide a return back into the NHS.”

Companies